Basic information

Biomarker: p16

Histology type: endometrioid endometrial carcinoma

Cohort characteristics

Country: USA

Region: MI

Followed up time :

Subgroup 1 name : negative in atypical polypoid adenomyoma

Subgroup 1 number: 0

Subgroup 2 name: positive in benign adenomyomatous polyps

Subgroup 2 number: 31

Total number Group I Group I number Group II Group II number Group III Group III number Group IV Group IV number
101 myoinvasive endometrioid endometrial carcinoma 30 adenomyomatous polyp 39 atypical polypoid adenomyoma 32

Sample information

Conclusion: Patchy to diffuse SATB2 and block-type p16 staining of fibromuscular stroma separating atypical endometrioid glands is more consistent with atypical polypoid adenomyomathan with myoinvasive endometrioid endometrial carcinoma .

Sample type : tissue

Sample method: staining

Expression pattern : patchy to diffuse SATB2 and block-type p16 staining

Expression elevation: The intensity (weak, moderate, or strong), extent (focal/patchy versus diffuse) and localisation (nuclear and/or cytoplasmic) of p16 staining in the stromal component of each lesion was recorded. Staining was considered to be diffuse when it was present in a majority (>50%) of cells. Blocktype p16 positivity was defined as clusters of continuous cells with strong nuclear or nuclear and cytoplasmic staining.

Disease information

Statictics: Mean

Cohort age: 47

Related information

Funtion Uniprot: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

UniProt ID: Q8N726

UniProt Link: https://www.uniprot.org/uniprotkb/Q8N726/entry#function

Biological function from UniProt: Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway

Molecular function from UniProt:

Subcellular UniProt: #Mitochondrion #Nucleus

Alternative name from UniProt:

Caution: The proteins described here are encoded by the gene CDKN2A, but are completely unrelated in terms of sequence and function to cyclin-dependent kinase inhibitor 2A (AC P42771) which is encoded by the same gene.

Recommended name: Tumor suppressor ARF

Gene name from HGNC: CDKN2A (ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf)

HPA class: Cancer-related genes Disease related genes Human disease related genes Plasma proteins

AlphaFold DB: Q8N726

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q8N726

HPA link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A

Tissue specificity RNA from HPA: Tissue enhanced (choroid plexus, pituitary gland)

Tissue expression from HPA: Mainly nuclear expression in most tissues.

Single cell type specificity Cell type enhanced (Late spermatids, Pancreatic endocrine cells, Early spermatids, Respiratory ciliated cells, Basal respiratory cells, Club cells)

Immune cell specificity: Immune cell enhanced (T-reg)

Subcellular summary HPA Located in Nucleoli (Single cell variability)

Cancer prognostic summary HPA Prognostic marker in endometrial cancer (unfavorable), renal cancer (unfavorable), liver cancer (unfavorable) and head and neck cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology/endometrial+cancer

OMIM: 600160

OMIM link2: https://www.omim.org/entry/600160

HGNC ID: HGNC:1787

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787

Visulization